1. Association of metabolic syndrome with risk of cardiovascular disease mortality and all-cause mortality among Malaysian adults: a retrospective cohort study
- Author
-
Kuang Hock Lim, Sumarni Mohd Ghazali, Hui Li Lim, Chien Huey Teh, Yong Kang Cheah, Kee Chee Cheong, Azli Baharudin, Abdul Muneer Abdul Hamid, Feisul Idzwan Mustapha, and Mohd Azahadi Omar
- Subjects
Medicine - Abstract
Objectives This study is aimed at determining the association between metabolic syndrome and risk of cardiovascular disease (CVD) mortality and all-cause mortality among Malaysian adults.Design Retrospective cohort study.Setting The Malaysian Non-Communicable Disease Surveillance (MyNCDS-1) 2005/2006.Participants A total of 2525 adults (1013 men and 1512 women), aged 24–64 years, who participated in the MyNCDS-1 2005/2006.Methods Participants’ anthropometric indices, blood pressure, fasting lipid profile and fasting blood glucose levels were evaluated to determine the prevalence of metabolic syndrome by the Harmonized criteria. Participants’ mortality status were followed up for 13 years from 2006 to 2018. Mortality data were obtained via record linkage with the Malaysian National Registration Department. The Cox proportional hazards regression model was applied to determine association between metabolic syndrome (MetS) and risk of CVD mortality and all-cause mortality with adjustment for selected sociodemographic and lifestyle behavioural factors.Results The overall point prevalence of MetS was 30.6% (95% CI: 28.0 to 33.3). Total follow-up time was 31 668 person-years with 213 deaths (111 (11.3%) in MetS subjects and 102 (6.1%) in non-MetS subjects) from all-causes, and 50 deaths (33 (2.9%) in MetS group and 17 (1.2%) in non-MetS group) from CVD. Metabolic syndrome was associated with a significantly increased hazard of CVD mortality (adjusted HR: 2.18 (95% CI: 1.03 to 4.61), p=0.041) and all-cause mortality (adjusted HR: 1.47 (95% CI: 1.00 to 2.14), p=0.048). These associations remained significant after excluding mortalities in the first 2 years.Conclusions Our study shows that individuals with MetS have a higher hazard of death from all-causes and CVD compared with those without MetS. It is thus imperative to prescribe individuals with MetS, a lifestyle intervention along with pharmacological intervention to improve the individual components of MetS and reduce this risk.
- Published
- 2021
- Full Text
- View/download PDF